

provides that a manufacturer who sells covered outpatient drugs to eligible (covered) entities must sign a pharmaceutical pricing agreement with the Secretary of HHS in which the manufacturer agrees to charge a price for covered outpatient drugs that will not exceed that amount determined under a statutory formula.

The purpose of this notice is to withdraw the **Federal Register** notice entitled, "Notice Regarding Section 602 of the Veterans Health Care Act of 1992—Rebate Mechanism," published on March 14, 1997. This notice requested comments on the proposal of a rebate process for State AIDS Drug Assistance Programs receiving funds under Title XXVI of the PHS Act.

FOR FURTHER INFORMATION CONTACT: Annette Byrne, R. Ph., Director, Office of Drug Pricing, Bureau of Primary Health Care, Health Resources and Services Administration, 4350 East West Highway, 10th Floor, Bethesda, MD 20814, Phone (301) 594-4353, Fax (301) 594-4982.

SUPPLEMENTARY INFORMATION: HRSA guidance for the section 340B drug program has described only a discount process for accessing 340B pricing. Although this discount system is functioning successfully for most covered entities, some State AIDS Drug Assistance Programs (ADAPs) have drug purchasing systems that have prevented their participation in the 340B drug program. The use of a rebate mechanism (in addition to the discount mechanism) should allow these groups to access 340B pricing.

Because the rebate mechanism is only a part of a larger endeavor by HRSA to develop the 340B drug program in such a manner as to effectively reach all covered entities, the notice outlining the concept of a narrowly-focused rebate mechanism is withdrawn for further internal deliberation.

Dated: March 14, 1997.

Ciro V. Sumaya,
Administrator.

[FR Doc. 97-7142 Filed 3-20-97; 8:45 am]

BILLING CODE 4160-15-P

National Institutes of Health

Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the Advisory Committee on Blood Safety and Availability, Department of Health and Human Services, March 20-21, 1997, which was published in the **Federal Register** on March 3, 1997 (62 FR 9441).

This meeting will be held on April 24-25, 1997, instead of the previously stated March 20-21. The Advisory meeting remains at the same time and place, 8:30 a.m., National Institutes of Health, Warren G. Magnuson Clinical Center, Jack Masur Auditorium, 9000 Rockville Pike, Bethesda, Maryland 20892. As previously stated, this meeting will be entirely open to the public.

On April 24, the Committee will discuss hepatitis C virus (HCV) infection, its occurrence following blood transfusion, other epidemiology of HCV infection and appropriate ways of approaching the public health aspects of this infection. On April 25, the Committee will address multiple aspects of the theoretical possibility that Creutzfeldt-Jakob disease (CJD) can be transmitted by blood transfusion. For each topic, a time will be set aside for the public to comment. Prospective speakers should notify the Executive Secretary for this meeting of their wish to present and should plan for no more than 5 minutes of comments.

CONTACT: Paul R. McCurdy, M.D., Acting Executive Secretary, Advisory Committee on Blood Safety and Availability, Director, Blood Resources Program, DBDR-MS-7950, NHLBI, NIH, Bethesda, Maryland 20892-7950. Phone: 301/435-0065; Fax 301/480-1060; E-Mail: paul_mccurdy@nih.gov.

Dated: March 17, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97-7129 Filed 3-20-97; 8:45 am]

BILLING CODE 4140-01-M

National Heart, Lung, and Blood Institutes; Notice of Meeting

Pursuant to Pub. L. 92-463, notice is hereby given of the meeting of the following National Heart, Lung, and Blood Institutes Special Emphasis Panel.

The meeting will be open to the public to provide concept review of proposed contract or grant solicitations.

Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should inform the Contract Person listed below in advance of the meeting.

Name of Panel: Stem Cell Transplantation in Sickle Cell Disease.

Dates of Meeting: April 30, 1997.

Time of Meeting: 10:00 a.m.

Place of Meeting: Two Rockledge Center, Rm. 9112, 6701 Rockledge Drive, Bethesda, Maryland 20892.

Agenda: To review current progress and identify future initiatives in the use of stem

cell transplantation for the treatment of sickle cell disease.

Contact Person: Helena Mishoe, Ph.D., NHLBI/DBDR, Two Rockledge Center, 6701 Rockledge Drive, Rm. 10156, MSC 7950, Bethesda, Maryland 20892, (301) 435-0050. (Catalog of Federal Domestic Assistance Programs Nos. 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; and 93.839, Blood Diseases and Resources Research, National Institutes of Health.)

Dated: March 17, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97-7128 Filed 3-20-97; 8:45 am]

BILLING CODE 4140-01-M

Prospective Grant of Exclusive License: Replicating Tumorcidal Viral Therapy for Cancer Applications

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This notice in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of a limited field of use exclusive license worldwide to practice the invention embodied in U.S. Patent Application Number 07/725,076 (issued on October 25, 1994 as U.S. Patent No. 5,358,866) entitled "Cytosine Deaminase Negative Selection System for Gene Transfer Techniques and Therapies" and its divisional applications 08/271,874, 08/447,580, 08/447,393, 08/445,203, 08/447,487, 08/449,627, 08/448,867, 08/449,636, and all related foreign filings, to ONYX, Inc., having a place of business in Richmond, CA (USA). The patent rights in these inventions have been assigned to the United States of America.

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 60 days from the date of this published Notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7. This notice modifies a previous notice of April 11, 1996 found in Volume 61, Number 71 of the **Federal Register**.

The field of use would be limited to Replicating Tumorcidal Viral Therapy for Cancer applications.

The present inventions relate to a modified bacterial gene for cytosine deaminase. Specifically, the CD gene can be used as a negative selectable

marker to transfect a targeted cell and deaminase a prodrug, 5-fluorocytosine ("5FC"), into 5-fluorouracil ("5FU") which has cytotoxic effects on the targeted cell.

ADDRESSES: Requests for copies of the subject issued patent and pending patent applications, inquiries, comments and other materials relating to the contemplated license should be directed to: Mr. Larry M. Tiffany, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852; Telephone: (301) 496-7056, ext. 206; Facsimile: (301) 402-0220. A signed Confidentiality Agreement will be required to receive copies of the pending patent applications. Applications for a license to the field of use described in this Notice will be treated as objections to the contemplated license. Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before May 20, 1997 will be considered. Comments and objections will not be made available for public inspection and, to the extent permitted by law, will not be subject to disclosure under the Freedom of Information Act, 5 U.S.C. 552.

Dated: March 11, 1997.

Barbara M. McGarey,

Deputy Director, Office of Technology Transfer.

[FR Doc. 97-7127 Filed 3-20-97; 8:45 am]

BILLING CODE 4140-01-M

Substance Abuse and Mental Health Services Administration (SAMHSA)

Notice of Meetings

Pursuant to Public Law 92-463, notice is hereby given of the Special Emphasis Panel II (SEP II) and the Center for Mental Health Services (CMHS) National Advisory Council meetings in April.

The SEP II meetings will include the review, discussion and evaluation of individual contract proposals. These discussions could reveal personal information concerning individuals associated with the proposals and confidential and financial information about an individual's proposal. These discussions may also reveal information about procurement activities exempt from disclosure by statute and trade secrets and commercial or financial information obtained from a person and privileged and confidential. Accordingly, the meetings are concerned with matters exempt from mandatory disclosure in Title 5 U.S.C.

552b(c) (3), (4), and (6) and 5 U.S.C. App. 2, § 10(d).

A summary of the meetings may be obtained from: Ms. Dee Herman, Committee Management Liaison, SAMHSA Office of Extramural Activities Review, 5600 Fishers Lane, Room 17-89, Rockville, Maryland 20857. Telephone (301) 443-4783.

Substantive program information may be obtained from the individual named as Contact for the meetings listed below.

Committee Name: SAMHSA Special Emphasis Panel II.

Meeting Date: April 7, 1997.

Place: DoubleTree Hotel, Randolph Room, 1750 Rockville Pike, Rockville, MD 20852.

Closed: April 7, 1997, 9:00 a.m.-Noon.

Contact: Sandra E. Stephens, Room 17-89, Parklawn Building, Telephone: (301) 443-9915 and FAX: (301) 443-3437.

Committee Name: SAMHSA Special Emphasis Panel II.

Meeting Date: April 7, 1997.

Place: DoubleTree Hotel, Randolph Room, 1750 Rockville Pike, Rockville, MD 20852.

Closed: April 7, 1997, 1:00 p.m.-4:00 p.m.

Contact: Sandra E. Stephens, Room 17-89, Parklawn Building, Telephone: (301) 443-9915 and FAX: (301) 443-3437.

The CMHS National Advisory Council meeting will include an open session with a roll call, general announcements and a discussion of review procedures. Public comments are welcome during the open session. Please communicate with the individual listed as Contact below for guidance.

The meeting will also include the review, discussion and evaluation of individual contract proposals. Therefore, a portion of the meeting will be closed to the public as determined by the Administrator, SAMHSA, in accordance with Title 5 U.S.C. 552b(c) (3), (4) and (6) and 5 U.S.C. App. 2, Section 10(d).

An agenda for the meeting and a roster of Council members may be obtained from Ms. Patricia Gratton, Committee Management Officer, CMHS, Room 11C-26, Parklawn Building, Rockville, Maryland. Telephone (301) 443-7987.

Substantive program information may be obtained from the individual named as Contact for the meeting listed below.

Committee Name: CMHS National Advisory Council.

Meeting Dates: April 10-11, 1997.

Place: DoubleTree Hotel at Pentagon City, Arlington North and South Conference Room, 300 Army Navy Drive, Arlington, Virginia 22202.

Closed: April 10, 8:30 a.m.-9:30 a.m.

Open: April 10, 9:30 a.m.-5:00 p.m.; April 11, 9:00 a.m.-Adjournment.

Contact: Ina B. Lyons, Room 13-103, Parklawn Building, Telephone: (301) 443-7586 and FAX: (301) 443-5163.

Dated: March 17, 1997.

Jeri Lipov,

Committee Management Officer, SAMHSA.

[FR Doc. 97-7146 Filed 3-20-97; 8:45 am]

BILLING CODE 4162-20-P

DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

[Docket No. FR-4200-N-44]

Submission for OMB Review: Comment Request

AGENCY: Office of Administration, HUD.

ACTION: Notice.

SUMMARY: The proposed information collection requirement described below has been submitted to the Office of Management and Budget (OMB) for review, as required by the Paperwork Reduction Act. The Department is soliciting public comments on the subject proposal.

DATES: Comments due date: April 21, 1997.

ADDRESSES: Interested persons are invited to submit comments regarding this proposal. Comments must be received within thirty (30) days from the date of this Notice. Comments should refer to the proposal by name and/or OMB approval number should be sent to: Joseph F. Lackey, Jr., OMB Desk Officer, Office of Management and Budget, Room 10235, New Executive Office Building, Washington, DC 20503.

FOR FURTHER INFORMATION CONTACT: Kay F. Weaver, Reports Management Officer, Department of Housing and Urban Development, 451 7th Street, Southwest, Washington, DC 20410, telephone (202) 708-0050. This is not a toll-free number. Copies of the proposed forms and other available documents submitted to OMB may be obtained from Ms. Weaver.

SUPPLEMENTARY INFORMATION: The Department has submitted the proposal for the collection of information, as described below, to OMB for review, as required by the Paperwork Reduction Act (44 U.S.C. Chapter 35).

The Notice lists the following information: (1) The title of the information collection proposal; (2) the office of the agency to collect the information; (3) the OMB approval number, if applicable; (4) the description of the need for the information and its proposed use; (5) the agency form number, if applicable; (6) what members of the public will be affected by the proposal; (7) how frequently information submissions will be required; (8) an estimate of the total